GLYXIA M

INDICATIONS:

• In patients with type 2 diabetes, GLYXIA M is indicated to improve glycemic control, as an adjunct to diet and exercise:
• In patients inadequately controlled on metformin alone at the maximum dose
• In combination with a sulfonylurea (triple therapy) when the maximum tolerated doses of metformin and a sulfonylurea do not achieve adequate glycemic control
• As an add-on to insulin (triple therapy) when insulin and metformin alone, at stable doses, do not achieve adequate glycemic control
• In triple therapy with a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist (thiazolidinedione) when the maximum tolerated doses of metformin and the PPARγ agonist do not achieve adequate glycemic control.

DOSAGE: The dosage of the antihyperglycemic treatment with GLYXIA-M must be adjusted for the patient based on their current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily dose of 100 mg of sitagliptin.